权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Protein and Energy Use in Pediatric Crohn's Disease

小儿克罗恩病的蛋白质和能量使用

基本信息

批准号：
7496004
负责人：
STEVEN J STEINER
金额：
$ 12.24万
依托单位：
INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS
依托单位国家：
美国
项目类别：
财政年份：
2006
资助国家：
美国
起止时间：
2006-09-28 至 2011-07-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/7496004
关键词：
Adrenal Cortex Hormones Albumins Amino Acids Anti-Inflammatory Agents Anti-inflammatory Antibodies Antibody Therapy Catabolism Child Child Care Childhood Clinical Research Crohn&apos s disease Diagnosis Disease Disease remission Early Diagnosis Education Energy Metabolism Enrollment Enteral Nutrition Environment Equilibrium Essential Amino Acids Failure Fasting Future Goals Growth Health Incidence Indirect Calorimetry Inflammatory Infusion procedures Isotopes Kinetics Knowledge Label Lead Master of Science Measurement Measures Medical Mentors Metabolic Methods Nutrient Nutritional Outcome Outpatients Parenteral Nutrition Planning Techniques Principal Investigator Property Prospective Studies Proteins Proteolysis Range Rate Relapse Research Research Personnel Rest Techniques Testing Training Tumor Necrosis Factor-alpha Tumor Necrosis Factors Visit Water Week Work cytokine expectation experience feeding human TNF protein infliximab innovation lipid metabolism metabolic abnormality assessment novel nutrition programs protein metabolism response skills stable isotope

项目摘要

DESCRIPTION (provided by applicant): More than one-third of children with Crohn's disease suffer from growth failure. Given the rising incidence and earlier diagnosis of Crohn's disease, nutrition and growth are critical outcomes for these children. There is a lack of knowledge concerning the response of these parameters to new therapies for Crohn's disease. Infliximab, an anti-tumor necrosis factor-alpha antibody, has revolutionized the care of children with Crohn's disease recalcitrant to corticosteroid therapy or complicated by fistulizing disease. We hypothesize that children with active Crohn's disease will have increased energy expenditure and proteolysis, and that treatment with infliximab will lead to greater improvement in these parameters than traditional corticosteroid therapy. To test these hypotheses, children with active relapsed Crohn's disease will be enrolled in a prospective study. Outpatient metabolic studies will be conducted just before, tow and fourteen weeks after initiation of corticosteroid of infliximab therapy. Using stable essential amino acid isotopes, rates of total body proteolysis and albumin synthesis can be measured in fasting, and enterally and parenterally fed states. Resting energy expenditure, using indirect calorimetry, and total energy expenditure, using doubly-labeled water, will be calculated at each visit. The proposed work is innovative, as it expands the knowledge of protein and energy use in response to traditional and novel therapies for pediatric Crohn's disease. These results will also help allow children with Crohn's disease to reach their true growth potential. The principal investigator, having completed a Masters of Science in Clinical Research, is in an established clinical research environment with a sponsor experienced in metabolic studies in children. Future training in nutrition and metabolic techniques are planned to further the principal investigator's education. This study will allow the principal investigator the opportunity to continue to develop clinical research skills in a mentored environment, with the expectation to expand these studies as an independent investigator in the future.

描述（由申请人提供）：